BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ISTO Technologies, Inc. to Present at the Jefferies 2010 Global Life Sciences Conference


6/1/2010 10:43:55 AM

ST. LOUIS, MO--(Marketwire - June 01, 2010) - ISTO Technologies, Inc. announced today that it will participate in the Jefferies 2010 Global Life Sciences Conference to be held in New York, NY on June 8-11, 2010. Mitchell Seyedin, Ph.D., President and CEO, is scheduled to provide a 30-minute overview of the Company at 8:30 a.m. Eastern Time on Thursday, June 10th. The conference will feature presentations from over 300 leading public and private healthcare companies across the life sciences spectrum, including biotechnology, life science tools, medical devices, diagnostics, specialty pharmaceuticals, and multi-national pharmaceutical companies.

The Company's leading cartilage regeneration product, DeNovo® ET, is a scaffold-free engineered cartilage tissue derived from expanded juvenile chondrocytes and is currently in human clinical trials for the repair of injured knee joints as an investigational product.

ISTO's second cell-based product in development, NuQu™, is an injectable formulation of juvenile cartilage cells intended for regeneration and repair of tissue lost to chronic disc diseases. NuQu is intended for minimally invasive intervention for patients suffering from discogenic back pain. ISTO commenced a Phase I clinical trial for NuQu under an IND approval from the FDA in early 2010.

In addition to ISTO's clinical-stage cell-based cartilage programs, the company is currently producing and marketing InQu®, a bone graft extender and substitute. InQu contains integrated hyaluronic acid and a synthetic polymer for better handling and biology. The primary target market for the product is spinal fusion applications.

About ISTO

ISTO is a privately-held orthobiologics Company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at www.istotech.com or contact Scott Gill, Chief Financial Officer, at 314-995-6049.


Contact:
Scott Gill
Chief Financial Officer
314-995-6049



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES